George Gives Take on Optimal Sequencing, Strategies in Pancreatic Cancer Pipeline
Dr. George discusses treatment considerations in the first-line setting of metastatic pancreatic cancer, signs that may indicate disease progression and the need for second-line therapy, and investigational agents in the pipeline.
Welcome to OncLive On Air®! I’m your host today, Jessica Hergert.
OncLive On Air® is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive® covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.
In today’s episode, sponsored by Ipsen, we had the pleasure of speaking with Ben George, MD, an associate professor of medicine (hematology and oncology), the director for practice integration of the Cancer, Genomic Sciences, and Precision Medicine Center at the Medical College of Wisconsin, to discuss the elements that go into therapeutic decision making in metastatic pancreatic cancer.
In our exclusive interview, George discussed treatment considerations in the first-line setting of metastatic pancreatic cancer, signs that may indicate disease progression and the need for second-line therapy, and investigational agents in the pipeline.
